Filariasis treatment sales will rise through 2036, driven by drugs at 82.6% of the drug type segment in 2026. Hospitals lead the end-user segment with a 47.9% share. The market was valued at USD 13.29 billion in 2025, reaching USD 14.6 billion in 2026 and USD 36.42 billion by 2036.